Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 54 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 54 participants) (very low certainty).

1 finding from 1 review

Intervention not reported

Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).

1 finding from 1 review